Minerva Neurosciences, Inc. (NERV) 10-Year Financial Performance & Capital Metrics

NERV • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Show more

Revenue $0
EBITDA -$22M +5.5%
Net Income $1M +104.8%
EPS (Diluted) 0.19 +104.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -4.79 -71.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 16.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM136.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM136.49%

ROCE

10Y Avg-40.07%

5Y Avg-39.95%

3Y Avg-44.09%

Latest-49.73%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	41.18M	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-1%	-	-	-
Cost of Goods Sold+	17.28K	0	11.09K	17.47K	161.51K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-17.28K	-16.53K	-11.09K	-17.47K	-162K	41.18M	0	0	0	0
Gross Margin %	-	-	-	-	-	1%	-	-	-	-
Gross Profit Growth %	-	0.04%	0.33%	-0.57%	-8.27%	255.17%	-1%	-	-	-
Operating Expenses+	26.11M	30.19M	41.17M	51.73M	75.86M	39.33M	45.37M	25.23M	23.12M	21.85M
OpEx % of Revenue	-	-	-	-	-	0.96%	-	-	-	-
Selling, General & Admin	7.58M	9.75M	10.91M	16.84M	17.74M	17.29M	13.33M	10.58M	10.41M	9.95M
SG&A % of Revenue	-	-	-	-	-	0.42%	-	-	-	-
Research & Development	18.53M	20.44M	30.26M	34.89M	58.12M	22.04M	32.04M	14.65M	12.71M	11.9M
R&D % of Revenue	-	-	-	-	-	0.54%	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-26.11M	-30.19M	-41.17M	-51.73M	-75.86M	1.85M	-45.37M	-25.23M	-23.12M	-21.85M
Operating Margin %	-	-	-	-	-	0.04%	-	-	-	-
Operating Income Growth %	0.52%	-0.16%	-0.36%	-0.26%	-0.47%	1.02%	-25.56%	0.44%	0.08%	0.05%
EBITDA+	-26.09M	-30.17M	-41.16M	-51.71M	-75.7M	2.02M	-45.26M	-25.22M	-23.09M	-21.83M
EBITDA Margin %	-	-	-	-	-	0.05%	-	-	-	-
EBITDA Growth %	0.52%	-0.16%	-0.36%	-0.26%	-0.46%	1.03%	-23.37%	0.44%	0.08%	0.05%
D&A (Non-Cash Add-back)	17.28K	16.53K	11.09K	17.47K	161.51K	176.18K	101.79K	8.51K	30.98K	22.47K
EBIT	-26.03M	-30.02M	-40.28M	-50.06M	-74.44M	1.94M	-45.38M	-24.7M	-21.72M	6M
Net Interest Income+	-956K	-832K	327.57K	1.56M	1.46M	0	-6.31M	-6.85M	-6.85M	-3.29M
Interest Income	96.91K	198K	941.83K	1.67M	1.46M	0	16.52K	556.95K	1.44M	1.27M
Interest Expense	1.05M	1.03M	614.26K	110.45K	0	0	6.33M	7.41M	8.28M	4.56M
Other Income/Expense	-972K	-855K	270.68K	1.56B	-17.57M	94.02K	-6.34M	-6.88M	-6.89M	23.29M
Pretax Income+	-27.08M	-31.05M	-40.9M	-50.17M	-74.44M	1.94M	-51.71M	-32.11M	-30.01M	1.44M
Pretax Margin %	-	-	-	-	-	0.05%	-	-	-	-
Income Tax+	0	0	-9.38M	1.67M	-2.25M	0	-1.8M	0	0	0
Effective Tax Rate %	1%	1%	0.77%	1%	0.97%	1%	0.97%	1%	1%	1%
Net Income+	-27.08M	-31.05M	-31.52M	-50.17M	-72.18M	1.94M	-49.91M	-32.11M	-30.01M	1.44M
Net Margin %	-	-	-	-	-	0.05%	-	-	-	-
Net Income Growth %	0.52%	-0.15%	-0.02%	-0.59%	-0.44%	1.03%	-26.71%	0.36%	0.07%	1.05%
Net Income (Continuing)	-27.08M	-31.05M	-31.52M	-50.17M	-72.18M	1.94M	-49.91M	-32.11M	-30.01M	1.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-9.25	-7.88	-6.65	-10.35	-14.80	0.38	-9.35	-6.01	-4.61	0.19
EPS Growth %	0.74%	0.15%	0.16%	-0.56%	-0.43%	1.03%	-25.61%	0.36%	0.23%	1.04%
EPS (Basic)	-9.25	-7.88	-6.65	-10.35	-14.80	0.38	-9.35	-6.01	-4.61	0.19
Diluted Shares Outstanding	2.93M	3.94M	4.74M	4.85M	4.88M	5.12M	5.34M	5.34M	6.51M	7.57M
Basic Shares Outstanding	2.93M	3.94M	4.74M	4.85M	4.88M	5.1M	5.34M	5.34M	6.51M	7.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	33.48M	83.86M	129.54M	90.02M	47.14M	27.44M	62.2M	40.16M	42M	22.27M
Cash & Short-Term Investments	32.2M	82.98M	128.16M	88M	45.85M	25.36M	60.76M	36.09M	40.91M	21.36M
Cash Only	14.28M	82.98M	26.05M	50.23M	21.41M	25.36M	60.76M	36.09M	40.91M	21.36M
Short-Term Investments	17.92M	0	102.11M	37.76M	24.44M	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	80K	80K	80K	100K	100K	100K	100K	4.07M	1.09M	906.89K
Total Non-Current Assets+	49.1M	49.08M	54.16M	49.12M	30.36M	30.19M	14.92M	14.93M	14.9M	14.87M
Property, Plant & Equipment	26.17K	9.64K	50.95K	33.48K	277.96K	101.79K	0	16.33K	10.88K	5.44K
Fixed Asset Turnover	-	-	-	-	-	404.54x	-	-	-	-
Goodwill	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M
Intangible Assets	34.2M	34.2M	34.2M	34.2M	15.2M	15.2M	51.08K	42.57K	17.03K	0
Long-Term Investments	0	0	5.02M	-5.29M	0	-2.35M	0	0	0	0
Other Non-Current Assets	0	0	-5.27M	14.81K	14.81K	14.81K	0	0	0	0
Total Assets+	82.58M	132.94M	183.7M	139.14M	77.5M	57.63M	77.12M	55.09M	56.9M	37.14M
Asset Turnover	-	-	-	-	-	0.71x	-	-	-	-
Asset Growth %	0.21%	0.61%	0.38%	-0.24%	-0.44%	-0.26%	0.34%	-0.29%	0.03%	-0.35%
Total Current Liabilities+	5.32M	9.69M	6.84M	3.61M	6.63M	3.16M	2.82M	1.38M	3.34M	2.84M
Accounts Payable	1.36M	1.47M	1.44M	1.8M	2.32M	995.61K	1.85M	969.67K	1.81M	1.61M
Days Payables Outstanding	28.75K	-	47.23K	37.61K	5.24K	-	-	-	-	-
Short-Term Debt	1.43M	4.85M	3.96M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	1.8M	0	1.43M	0	0	31.88K	0	14.83K	590.77K	363.18K
Current Ratio	6.29x	8.66x	18.94x	24.94x	7.11x	8.68x	22.07x	29.15x	12.57x	7.85x
Quick Ratio	6.29x	8.66x	18.94x	24.94x	7.11x	8.68x	22.07x	29.15x	12.57x	7.85x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	21.94M	17.27M	45.26M	45.26M	43.09M	1.8M	66.33M	73.73M	82.02M	60M
Long-Term Debt	8.5M	3.84M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	111.23K	0	0	0	0	0
Deferred Tax Liabilities	13.43M	13.43M	4.06M	4.06M	1.8M	1.8M	0	0	0	0
Other Non-Current Liabilities	0	0	29.88K	28.99K	0	0	66.33M	73.73M	82.02M	60M
Total Liabilities	27.26M	26.96M	52.1M	48.87M	49.72M	4.96M	69.15M	75.11M	85.36M	62.84M
Total Debt+	9.94M	8.69M	3.96M	0	284.13K	111.23K	0	0	0	0
Net Debt	-4.35M	-74.29M	-22.09M	-50.23M	-21.13M	-25.25M	-60.76M	-36.09M	-40.91M	-21.36M
Debt / Equity	0.18x	0.08x	0.03x	-	0.01x	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	0.05x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-12.48x	-	-	-	-
Interest Coverage	-24.80x	-29.31x	-67.02x	-468.37x	-	-	-7.17x	-3.41x	-2.79x	-4.79x
Total Equity+	55.32M	105.98M	131.6M	90.26M	27.78M	52.66M	7.98M	-20.02M	-28.46M	-25.69M
Equity Growth %	0.07%	0.92%	0.24%	-0.31%	-0.69%	0.9%	-0.85%	-3.51%	-0.42%	0.1%
Book Value per Share	18.90	26.91	27.75	18.62	5.70	10.30	1.49	-3.75	-4.37	-3.39
Total Shareholders' Equity	55.32M	105.98M	131.6M	90.26M	27.78M	52.66M	7.98M	-20.02M	-28.46M	-25.69M
Common Stock	2.47K	3.5K	3.88K	3.89K	3.91K	4.27K	534	534	699	699
Retained Earnings	-101.81M	-132.86M	-164.38M	-214.55M	-286.74M	-284.8M	-334.7M	-366.81M	-396.82M	-395.38M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-24.27M	-25.69M	3.09M	-41.94M	-43.43M	-33.82M	-24.6M	-24.65M	-14.78M	-19.55M
Operating CF Margin %	-	-	-	-	-	-0.82%	-	-	-	-
Operating CF Growth %	0.33%	-0.06%	1.12%	-14.56%	-0.04%	0.22%	0.27%	-0%	0.4%	-0.32%
Net Income	-27.08M	-31.05M	-31.52M	-50.17M	-72.18M	1.94M	-49.91M	-32.11M	-30.01M	1.44M
Depreciation & Amortization	17.28K	16.53K	11.09K	17.47K	161.51K	176.18K	101.79K	8.51K	30.98K	22.47K
Stock-Based Compensation	2.2M	3.57M	5.03M	8.18M	0	9.7M	5.22M	4.11M	1.97M	1.33M
Deferred Taxes	247.26K	102.63K	-9.38M	-119.61K	-2.25M	0	-1.8M	0	0	0
Other Non-Cash Items	377.45K	347.77K	21.07K	38.04K	27.41M	-86.77K	21.53M	7.41M	8.28M	-22.02M
Working Capital Changes	-32.02K	1.32M	38.93M	110.96K	3.43M	-45.56M	259.33K	-4.06M	4.94M	-320.6K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	718.76K	107.77K	-32.7K	364.03K	517.34K	-1.32M	857.6K	-883.55K	835.65K	-197.48K
Cash from Investing+	-18.33M	17.82M	-107.19M	69.49M	14.08M	24.53M	0	-16.33K	0	0
Capital Expenditures	0	0	-52.4K	0	0	0	0	-16.33K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-44.99K	0	-52.4M	0	0	0	0	0	0	0
Cash from Financing+	38.34M	76.57M	47.17M	-3.34M	525K	13.24M	60M	-5	19.6M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-195.66K	19.64M	7.54M	655.93K	0	687.99K	60M	-5	-396.29K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-24.27M	-25.69M	3.04M	-41.94M	-43.43M	-33.82M	-24.6M	-24.66M	-14.78M	-19.55M
FCF Margin %	-	-	-	-	-	-0.82%	-	-	-	-
FCF Growth %	0.33%	-0.06%	1.12%	-14.79%	-0.04%	0.22%	0.27%	-0%	0.4%	-0.32%
FCF per Share	-8.29	-6.52	0.64	-8.65	-8.91	-6.61	-4.61	-4.62	-2.27	-2.58
FCF Conversion (FCF/Net Income)	0.90x	0.83x	-0.10x	0.84x	0.60x	-17.43x	0.49x	0.77x	0.49x	-13.59x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-50.71%	-38.49%	-26.54%	-45.23%	-122.3%	4.83%	-164.6%	-	-	-
Return on Invested Capital (ROIC)	-46.67%	-54.78%	-43.73%	-51.89%	-243.78%	8.13%	-	-	-	-
Gross Margin	-	-	-	-	-	100%	-	-	-	-
Net Margin	-	-	-	-	-	4.71%	-	-	-	-
Debt / Equity	0.18x	0.08x	0.03x	-	0.01x	0.00x	-	-	-	-
Interest Coverage	-24.80x	-29.31x	-67.02x	-468.37x	-	-	-7.17x	-3.41x	-2.79x	-4.79x
FCF Conversion	0.90x	0.83x	-0.10x	0.84x	0.60x	-17.43x	0.49x	0.77x	0.49x	-13.59x
Revenue Growth	-	-	-	-	-	-	-100%	-	-	-

Frequently Asked Questions

Valuation & Price

Minerva Neurosciences, Inc. (NERV) has a price-to-earnings (P/E) ratio of 22.8x. This is roughly in line with market averages.

Growth & Financials

Minerva Neurosciences, Inc. (NERV) grew revenue by 0.0% over the past year. Growth has been modest.

Yes, Minerva Neurosciences, Inc. (NERV) is profitable, generating $12.2M in net income for fiscal year 2024.

Dividend & Returns

Minerva Neurosciences, Inc. (NERV) had negative free cash flow of $14.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Minerva Neurosciences, Inc. (NERV) 10-Year Financial Performance & Capital Metrics

NERV • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$22M +5.5%
Net Income $1M +104.8%
EPS (Diluted) 0.19 +104.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -4.79 -71.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 16.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM136.38%

EPS CAGR

10Y-

5Y-

3Y-

TTM136.49%

ROCE

10Y Avg-40.07%

5Y Avg-39.95%

3Y Avg-44.09%

Latest-49.73%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	41.18M	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-1%	-	-	-
Cost of Goods Sold+	17.28K	0	11.09K	17.47K	161.51K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-17.28K	-16.53K	-11.09K	-17.47K	-162K	41.18M	0	0	0	0
Gross Margin %	-	-	-	-	-	1%	-	-	-	-
Gross Profit Growth %	-	0.04%	0.33%	-0.57%	-8.27%	255.17%	-1%	-	-	-
Operating Expenses+	26.11M	30.19M	41.17M	51.73M	75.86M	39.33M	45.37M	25.23M	23.12M	21.85M
OpEx % of Revenue	-	-	-	-	-	0.96%	-	-	-	-
Selling, General & Admin	7.58M	9.75M	10.91M	16.84M	17.74M	17.29M	13.33M	10.58M	10.41M	9.95M
SG&A % of Revenue	-	-	-	-	-	0.42%	-	-	-	-
Research & Development	18.53M	20.44M	30.26M	34.89M	58.12M	22.04M	32.04M	14.65M	12.71M	11.9M
R&D % of Revenue	-	-	-	-	-	0.54%	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-26.11M	-30.19M	-41.17M	-51.73M	-75.86M	1.85M	-45.37M	-25.23M	-23.12M	-21.85M
Operating Margin %	-	-	-	-	-	0.04%	-	-	-	-
Operating Income Growth %	0.52%	-0.16%	-0.36%	-0.26%	-0.47%	1.02%	-25.56%	0.44%	0.08%	0.05%
EBITDA+	-26.09M	-30.17M	-41.16M	-51.71M	-75.7M	2.02M	-45.26M	-25.22M	-23.09M	-21.83M
EBITDA Margin %	-	-	-	-	-	0.05%	-	-	-	-
EBITDA Growth %	0.52%	-0.16%	-0.36%	-0.26%	-0.46%	1.03%	-23.37%	0.44%	0.08%	0.05%
D&A (Non-Cash Add-back)	17.28K	16.53K	11.09K	17.47K	161.51K	176.18K	101.79K	8.51K	30.98K	22.47K
EBIT	-26.03M	-30.02M	-40.28M	-50.06M	-74.44M	1.94M	-45.38M	-24.7M	-21.72M	6M
Net Interest Income+	-956K	-832K	327.57K	1.56M	1.46M	0	-6.31M	-6.85M	-6.85M	-3.29M
Interest Income	96.91K	198K	941.83K	1.67M	1.46M	0	16.52K	556.95K	1.44M	1.27M
Interest Expense	1.05M	1.03M	614.26K	110.45K	0	0	6.33M	7.41M	8.28M	4.56M
Other Income/Expense	-972K	-855K	270.68K	1.56B	-17.57M	94.02K	-6.34M	-6.88M	-6.89M	23.29M
Pretax Income+	-27.08M	-31.05M	-40.9M	-50.17M	-74.44M	1.94M	-51.71M	-32.11M	-30.01M	1.44M
Pretax Margin %	-	-	-	-	-	0.05%	-	-	-	-
Income Tax+	0	0	-9.38M	1.67M	-2.25M	0	-1.8M	0	0	0
Effective Tax Rate %	1%	1%	0.77%	1%	0.97%	1%	0.97%	1%	1%	1%
Net Income+	-27.08M	-31.05M	-31.52M	-50.17M	-72.18M	1.94M	-49.91M	-32.11M	-30.01M	1.44M
Net Margin %	-	-	-	-	-	0.05%	-	-	-	-
Net Income Growth %	0.52%	-0.15%	-0.02%	-0.59%	-0.44%	1.03%	-26.71%	0.36%	0.07%	1.05%
Net Income (Continuing)	-27.08M	-31.05M	-31.52M	-50.17M	-72.18M	1.94M	-49.91M	-32.11M	-30.01M	1.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-9.25	-7.88	-6.65	-10.35	-14.80	0.38	-9.35	-6.01	-4.61	0.19
EPS Growth %	0.74%	0.15%	0.16%	-0.56%	-0.43%	1.03%	-25.61%	0.36%	0.23%	1.04%
EPS (Basic)	-9.25	-7.88	-6.65	-10.35	-14.80	0.38	-9.35	-6.01	-4.61	0.19
Diluted Shares Outstanding	2.93M	3.94M	4.74M	4.85M	4.88M	5.12M	5.34M	5.34M	6.51M	7.57M
Basic Shares Outstanding	2.93M	3.94M	4.74M	4.85M	4.88M	5.1M	5.34M	5.34M	6.51M	7.57M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	33.48M	83.86M	129.54M	90.02M	47.14M	27.44M	62.2M	40.16M	42M	22.27M
Cash & Short-Term Investments	32.2M	82.98M	128.16M	88M	45.85M	25.36M	60.76M	36.09M	40.91M	21.36M
Cash Only	14.28M	82.98M	26.05M	50.23M	21.41M	25.36M	60.76M	36.09M	40.91M	21.36M
Short-Term Investments	17.92M	0	102.11M	37.76M	24.44M	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	80K	80K	80K	100K	100K	100K	100K	4.07M	1.09M	906.89K
Total Non-Current Assets+	49.1M	49.08M	54.16M	49.12M	30.36M	30.19M	14.92M	14.93M	14.9M	14.87M
Property, Plant & Equipment	26.17K	9.64K	50.95K	33.48K	277.96K	101.79K	0	16.33K	10.88K	5.44K
Fixed Asset Turnover	-	-	-	-	-	404.54x	-	-	-	-
Goodwill	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M	14.87M
Intangible Assets	34.2M	34.2M	34.2M	34.2M	15.2M	15.2M	51.08K	42.57K	17.03K	0
Long-Term Investments	0	0	5.02M	-5.29M	0	-2.35M	0	0	0	0
Other Non-Current Assets	0	0	-5.27M	14.81K	14.81K	14.81K	0	0	0	0
Total Assets+	82.58M	132.94M	183.7M	139.14M	77.5M	57.63M	77.12M	55.09M	56.9M	37.14M
Asset Turnover	-	-	-	-	-	0.71x	-	-	-	-
Asset Growth %	0.21%	0.61%	0.38%	-0.24%	-0.44%	-0.26%	0.34%	-0.29%	0.03%	-0.35%
Total Current Liabilities+	5.32M	9.69M	6.84M	3.61M	6.63M	3.16M	2.82M	1.38M	3.34M	2.84M
Accounts Payable	1.36M	1.47M	1.44M	1.8M	2.32M	995.61K	1.85M	969.67K	1.81M	1.61M
Days Payables Outstanding	28.75K	-	47.23K	37.61K	5.24K	-	-	-	-	-
Short-Term Debt	1.43M	4.85M	3.96M	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	0	0	0
Other Current Liabilities	1.8M	0	1.43M	0	0	31.88K	0	14.83K	590.77K	363.18K
Current Ratio	6.29x	8.66x	18.94x	24.94x	7.11x	8.68x	22.07x	29.15x	12.57x	7.85x
Quick Ratio	6.29x	8.66x	18.94x	24.94x	7.11x	8.68x	22.07x	29.15x	12.57x	7.85x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	21.94M	17.27M	45.26M	45.26M	43.09M	1.8M	66.33M	73.73M	82.02M	60M
Long-Term Debt	8.5M	3.84M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	111.23K	0	0	0	0	0
Deferred Tax Liabilities	13.43M	13.43M	4.06M	4.06M	1.8M	1.8M	0	0	0	0
Other Non-Current Liabilities	0	0	29.88K	28.99K	0	0	66.33M	73.73M	82.02M	60M
Total Liabilities	27.26M	26.96M	52.1M	48.87M	49.72M	4.96M	69.15M	75.11M	85.36M	62.84M
Total Debt+	9.94M	8.69M	3.96M	0	284.13K	111.23K	0	0	0	0
Net Debt	-4.35M	-74.29M	-22.09M	-50.23M	-21.13M	-25.25M	-60.76M	-36.09M	-40.91M	-21.36M
Debt / Equity	0.18x	0.08x	0.03x	-	0.01x	0.00x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	0.05x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-12.48x	-	-	-	-
Interest Coverage	-24.80x	-29.31x	-67.02x	-468.37x	-	-	-7.17x	-3.41x	-2.79x	-4.79x
Total Equity+	55.32M	105.98M	131.6M	90.26M	27.78M	52.66M	7.98M	-20.02M	-28.46M	-25.69M
Equity Growth %	0.07%	0.92%	0.24%	-0.31%	-0.69%	0.9%	-0.85%	-3.51%	-0.42%	0.1%
Book Value per Share	18.90	26.91	27.75	18.62	5.70	10.30	1.49	-3.75	-4.37	-3.39
Total Shareholders' Equity	55.32M	105.98M	131.6M	90.26M	27.78M	52.66M	7.98M	-20.02M	-28.46M	-25.69M
Common Stock	2.47K	3.5K	3.88K	3.89K	3.91K	4.27K	534	534	699	699
Retained Earnings	-101.81M	-132.86M	-164.38M	-214.55M	-286.74M	-284.8M	-334.7M	-366.81M	-396.82M	-395.38M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-24.27M	-25.69M	3.09M	-41.94M	-43.43M	-33.82M	-24.6M	-24.65M	-14.78M	-19.55M
Operating CF Margin %	-	-	-	-	-	-0.82%	-	-	-	-
Operating CF Growth %	0.33%	-0.06%	1.12%	-14.56%	-0.04%	0.22%	0.27%	-0%	0.4%	-0.32%
Net Income	-27.08M	-31.05M	-31.52M	-50.17M	-72.18M	1.94M	-49.91M	-32.11M	-30.01M	1.44M
Depreciation & Amortization	17.28K	16.53K	11.09K	17.47K	161.51K	176.18K	101.79K	8.51K	30.98K	22.47K
Stock-Based Compensation	2.2M	3.57M	5.03M	8.18M	0	9.7M	5.22M	4.11M	1.97M	1.33M
Deferred Taxes	247.26K	102.63K	-9.38M	-119.61K	-2.25M	0	-1.8M	0	0	0
Other Non-Cash Items	377.45K	347.77K	21.07K	38.04K	27.41M	-86.77K	21.53M	7.41M	8.28M	-22.02M
Working Capital Changes	-32.02K	1.32M	38.93M	110.96K	3.43M	-45.56M	259.33K	-4.06M	4.94M	-320.6K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	718.76K	107.77K	-32.7K	364.03K	517.34K	-1.32M	857.6K	-883.55K	835.65K	-197.48K
Cash from Investing+	-18.33M	17.82M	-107.19M	69.49M	14.08M	24.53M	0	-16.33K	0	0
Capital Expenditures	0	0	-52.4K	0	0	0	0	-16.33K	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-44.99K	0	-52.4M	0	0	0	0	0	0	0
Cash from Financing+	38.34M	76.57M	47.17M	-3.34M	525K	13.24M	60M	-5	19.6M	0
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-195.66K	19.64M	7.54M	655.93K	0	687.99K	60M	-5	-396.29K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-24.27M	-25.69M	3.04M	-41.94M	-43.43M	-33.82M	-24.6M	-24.66M	-14.78M	-19.55M
FCF Margin %	-	-	-	-	-	-0.82%	-	-	-	-
FCF Growth %	0.33%	-0.06%	1.12%	-14.79%	-0.04%	0.22%	0.27%	-0%	0.4%	-0.32%
FCF per Share	-8.29	-6.52	0.64	-8.65	-8.91	-6.61	-4.61	-4.62	-2.27	-2.58
FCF Conversion (FCF/Net Income)	0.90x	0.83x	-0.10x	0.84x	0.60x	-17.43x	0.49x	0.77x	0.49x	-13.59x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-50.71%	-38.49%	-26.54%	-45.23%	-122.3%	4.83%	-164.6%	-	-	-
Return on Invested Capital (ROIC)	-46.67%	-54.78%	-43.73%	-51.89%	-243.78%	8.13%	-	-	-	-
Gross Margin	-	-	-	-	-	100%	-	-	-	-
Net Margin	-	-	-	-	-	4.71%	-	-	-	-
Debt / Equity	0.18x	0.08x	0.03x	-	0.01x	0.00x	-	-	-	-
Interest Coverage	-24.80x	-29.31x	-67.02x	-468.37x	-	-	-7.17x	-3.41x	-2.79x	-4.79x
FCF Conversion	0.90x	0.83x	-0.10x	0.84x	0.60x	-17.43x	0.49x	0.77x	0.49x	-13.59x
Revenue Growth	-	-	-	-	-	-	-100%	-	-	-

Frequently Asked Questions

Valuation & Price

Minerva Neurosciences, Inc. (NERV) has a price-to-earnings (P/E) ratio of 22.8x. This is roughly in line with market averages.

Growth & Financials

Minerva Neurosciences, Inc. (NERV) grew revenue by 0.0% over the past year. Growth has been modest.

Yes, Minerva Neurosciences, Inc. (NERV) is profitable, generating $12.2M in net income for fiscal year 2024.

Dividend & Returns

Minerva Neurosciences, Inc. (NERV) had negative free cash flow of $14.5M in fiscal year 2024, likely due to heavy capital investments.